Insulin therapy during Ramadan fast for Type 1 diabetes patients

Hania Kassem, M. S. Zantout, S. T. Azar

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Patients with Type 1 diabetes (T1D) are normally exempt from the Ramadan fast; however, some patients insist on following the fast, often without the approval of their physicians. The aim of this study is to provide patients with T1D, who insist on fasting, with the most appropriate insulin regimen during the month of Ramadan. Seventeen patients with T1D who insisted on fasting were studied. Prior to Ramadan, the intermediate insulin was changed to ultralente in all patients. The total dose of insulin given to fasting patients by the end of Ramadan (45.7±14.4 U/day) was less than the total dose of insulin given before fasting (52.8±13.1 U/day) p<0.05. The ultralente and regular insulin constituted 70 and 30%, respectively, of the total insulin dose by the end of Ramadan, divided equally between Suhur (before sunrise) and Iftar (after sunset). There was no change in the glycosylated hemoglobin before and after fasting. Patients were instructed to break their fast after any episode of hypoglycemia. There were no severe daytime hypoglycemia episodes. We recommend that patients with T1D wishing to fast be switched to long acting insulin such as ultralente. The total insulin dose should consist of around 85% of their initial insulin dose and it should be composed of around 70% ultralente and 30% rapid insulin, divided equally between Suhur and Iftar.

Original languageEnglish (US)
Pages (from-to)802-805
Number of pages4
JournalJournal of Endocrinological Investigation
Volume28
Issue number9
StatePublished - 2005
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Insulin
Fasting
Therapeutics
Hypoglycemia
Ultralente Insulin
Long-Acting Insulin
Glycosylated Hemoglobin A
Physicians

Keywords

  • Insulin therapy
  • Ramadan fasting
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology

Cite this

Insulin therapy during Ramadan fast for Type 1 diabetes patients. / Kassem, Hania; Zantout, M. S.; Azar, S. T.

In: Journal of Endocrinological Investigation, Vol. 28, No. 9, 2005, p. 802-805.

Research output: Contribution to journalArticle

@article{1e7c391b88e04dad955d21d1e7a4e43b,
title = "Insulin therapy during Ramadan fast for Type 1 diabetes patients",
abstract = "Patients with Type 1 diabetes (T1D) are normally exempt from the Ramadan fast; however, some patients insist on following the fast, often without the approval of their physicians. The aim of this study is to provide patients with T1D, who insist on fasting, with the most appropriate insulin regimen during the month of Ramadan. Seventeen patients with T1D who insisted on fasting were studied. Prior to Ramadan, the intermediate insulin was changed to ultralente in all patients. The total dose of insulin given to fasting patients by the end of Ramadan (45.7±14.4 U/day) was less than the total dose of insulin given before fasting (52.8±13.1 U/day) p<0.05. The ultralente and regular insulin constituted 70 and 30{\%}, respectively, of the total insulin dose by the end of Ramadan, divided equally between Suhur (before sunrise) and Iftar (after sunset). There was no change in the glycosylated hemoglobin before and after fasting. Patients were instructed to break their fast after any episode of hypoglycemia. There were no severe daytime hypoglycemia episodes. We recommend that patients with T1D wishing to fast be switched to long acting insulin such as ultralente. The total insulin dose should consist of around 85{\%} of their initial insulin dose and it should be composed of around 70{\%} ultralente and 30{\%} rapid insulin, divided equally between Suhur and Iftar.",
keywords = "Insulin therapy, Ramadan fasting, Type 1 diabetes",
author = "Hania Kassem and Zantout, {M. S.} and Azar, {S. T.}",
year = "2005",
language = "English (US)",
volume = "28",
pages = "802--805",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "9",

}

TY - JOUR

T1 - Insulin therapy during Ramadan fast for Type 1 diabetes patients

AU - Kassem, Hania

AU - Zantout, M. S.

AU - Azar, S. T.

PY - 2005

Y1 - 2005

N2 - Patients with Type 1 diabetes (T1D) are normally exempt from the Ramadan fast; however, some patients insist on following the fast, often without the approval of their physicians. The aim of this study is to provide patients with T1D, who insist on fasting, with the most appropriate insulin regimen during the month of Ramadan. Seventeen patients with T1D who insisted on fasting were studied. Prior to Ramadan, the intermediate insulin was changed to ultralente in all patients. The total dose of insulin given to fasting patients by the end of Ramadan (45.7±14.4 U/day) was less than the total dose of insulin given before fasting (52.8±13.1 U/day) p<0.05. The ultralente and regular insulin constituted 70 and 30%, respectively, of the total insulin dose by the end of Ramadan, divided equally between Suhur (before sunrise) and Iftar (after sunset). There was no change in the glycosylated hemoglobin before and after fasting. Patients were instructed to break their fast after any episode of hypoglycemia. There were no severe daytime hypoglycemia episodes. We recommend that patients with T1D wishing to fast be switched to long acting insulin such as ultralente. The total insulin dose should consist of around 85% of their initial insulin dose and it should be composed of around 70% ultralente and 30% rapid insulin, divided equally between Suhur and Iftar.

AB - Patients with Type 1 diabetes (T1D) are normally exempt from the Ramadan fast; however, some patients insist on following the fast, often without the approval of their physicians. The aim of this study is to provide patients with T1D, who insist on fasting, with the most appropriate insulin regimen during the month of Ramadan. Seventeen patients with T1D who insisted on fasting were studied. Prior to Ramadan, the intermediate insulin was changed to ultralente in all patients. The total dose of insulin given to fasting patients by the end of Ramadan (45.7±14.4 U/day) was less than the total dose of insulin given before fasting (52.8±13.1 U/day) p<0.05. The ultralente and regular insulin constituted 70 and 30%, respectively, of the total insulin dose by the end of Ramadan, divided equally between Suhur (before sunrise) and Iftar (after sunset). There was no change in the glycosylated hemoglobin before and after fasting. Patients were instructed to break their fast after any episode of hypoglycemia. There were no severe daytime hypoglycemia episodes. We recommend that patients with T1D wishing to fast be switched to long acting insulin such as ultralente. The total insulin dose should consist of around 85% of their initial insulin dose and it should be composed of around 70% ultralente and 30% rapid insulin, divided equally between Suhur and Iftar.

KW - Insulin therapy

KW - Ramadan fasting

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=31544437166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544437166&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 802

EP - 805

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 9

ER -